BSE Live
Nov 07, 16:01Prev. Close
1140.55
Open Price
1142.00
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Nov 07, 15:58Prev. Close
1140.60
Open Price
1141.50
Bid Price (Qty.)
1123.80 (103)
Offer Price (Qty.)
0.00 (0)
| Balance Sheet of Aurobindo Pharma (in Rs. Cr.) | Mar 20 | Mar 19 | Mar 18 | Mar 17 | Mar 16 | |
| 12 mths | 12 mths | 12 mths | 12 mths | 12 mths | ||
| EQUITIES AND LIABILITIES | ||||||
| SHAREHOLDER'S FUNDS | ||||||
| Equity Share Capital | 58.59 | 58.59 | 58.59 | 58.59 | 58.52 | |
| Total Share Capital | 58.59 | 58.59 | 58.59 | 58.59 | 58.52 | |
| Reserves and Surplus | 12,966.97 | 11,292.03 | 9,923.99 | 8,377.59 | 6,807.33 | |
| Total Reserves and Surplus | 12,966.97 | 11,292.03 | 9,923.99 | 8,377.59 | 6,807.33 | |
| Total Shareholders Funds | 13,025.56 | 11,350.62 | 9,982.58 | 8,436.18 | 6,865.85 | |
| NON-CURRENT LIABILITIES | ||||||
| Long Term Borrowings | 0.00 | 0.00 | 0.00 | 118.90 | 334.76 | |
| Deferred Tax Liabilities [Net] | 95.53 | 31.00 | 23.48 | 0.00 | 0.00 | |
| Other Long Term Liabilities | 11.14 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Long Term Provisions | 42.44 | 22.64 | 33.60 | 20.87 | 21.26 | |
| Total Non-Current Liabilities | 149.11 | 53.64 | 57.08 | 139.77 | 356.02 | |
| CURRENT LIABILITIES | ||||||
| Short Term Borrowings | 3,730.32 | 4,519.80 | 3,653.83 | 2,751.27 | 3,417.15 | |
| Trade Payables | 1,914.53 | 1,841.39 | 1,629.24 | 1,217.60 | 1,278.67 | |
| Other Current Liabilities | 600.19 | 278.76 | 396.57 | 416.60 | 597.94 | |
| Short Term Provisions | 114.86 | 96.51 | 74.54 | 61.50 | 49.93 | |
| Total Current Liabilities | 6,359.90 | 6,736.46 | 5,754.18 | 4,446.97 | 5,343.69 | |
| Total Capital And Liabilities | 19,534.57 | 18,140.72 | 15,793.84 | 13,022.92 | 12,565.56 | |
| ASSETS | ||||||
| NON-CURRENT ASSETS | ||||||
| Tangible Assets | 4,361.80 | 4,145.85 | 3,392.97 | 3,211.62 | 2,568.13 | |
| Intangible Assets | 2.89 | 3.85 | 0.00 | 0.00 | 0.00 | |
| Capital Work-In-Progress | 726.62 | 750.07 | 1,100.23 | 878.31 | 742.14 | |
| Other Assets | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Fixed Assets | 5,091.31 | 4,938.71 | 4,536.95 | 4,118.60 | 3,310.27 | |
| Non-Current Investments | 2,519.68 | 2,339.04 | 1,967.48 | 1,681.93 | 1,183.33 | |
| Deferred Tax Assets [Net] | 0.00 | 0.00 | 0.00 | 0.08 | 6.86 | |
| Long Term Loans And Advances | 427.24 | 146.56 | 13.26 | 46.36 | 29.60 | |
| Other Non-Current Assets | 248.25 | 308.07 | 294.95 | 272.60 | 261.00 | |
| Total Non-Current Assets | 8,286.48 | 7,732.38 | 6,812.64 | 6,119.57 | 4,791.06 | |
| CURRENT ASSETS | ||||||
| Current Investments | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | |
| Inventories | 4,314.56 | 3,971.26 | 3,409.23 | 2,433.62 | 2,431.60 | |
| Trade Receivables | 5,789.57 | 5,232.07 | 4,468.23 | 3,773.63 | 4,380.97 | |
| Cash And Cash Equivalents | 78.25 | 75.77 | 245.90 | 33.64 | 330.81 | |
| Short Term Loans And Advances | 12.15 | 9.82 | 8.23 | 10.25 | 9.48 | |
| OtherCurrentAssets | 1,053.54 | 1,119.40 | 849.59 | 652.19 | 621.62 | |
| Total Current Assets | 11,248.09 | 10,408.34 | 8,981.20 | 6,903.35 | 7,774.50 | |
| Total Assets | 19,534.57 | 18,140.72 | 15,793.84 | 13,022.92 | 12,565.56 | |
| OTHER ADDITIONAL INFORMATION | ||||||
| CONTINGENT LIABILITIES, COMMITMENTS | ||||||
| Contingent Liabilities | 2,174.36 | 2,736.18 | 1,480.23 | 0.00 | 0.00 | |
| CIF VALUE OF IMPORTS | ||||||
| Raw Materials | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Stores, Spares And Loose Tools | 3,490.17 | 3,674.13 | 0.00 | 0.00 | 0.00 | |
| Trade/Other Goods | 3,490.17 | 3,674.13 | 0.00 | 0.00 | 0.00 | |
| Capital Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| EXPENDITURE IN FOREIGN EXCHANGE | ||||||
| Expenditure In Foreign Currency | 408.93 | 384.78 | 3,470.03 | 3,022.43 | 2,879.84 | |
| REMITTANCES IN FOREIGN CURRENCIES FOR DIVIDENDS | ||||||
| Dividend Remittance In Foreign Currency | -- | -- | -- | -- | -- | |
| EARNINGS IN FOREIGN EXCHANGE | ||||||
| FOB Value Of Goods | 10,712.59 | 9,709.12 | 8,068.05 | 7,576.07 | 7,092.68 | |
| Other Earnings | 31.88 | 22.52 | 4.67 | 7.70 | 8.83 | |
| BONUS DETAILS | ||||||
| Bonus Equity Share Capital | 46.55 | 46.55 | 46.55 | 46.55 | 46.55 | |
| NON-CURRENT INVESTMENTS | ||||||
| Non-Current Investments Quoted Market Value | -- | -- | -- | -- | -- | |
| Non-Current Investments Unquoted Book Value | 2,519.68 | 2,339.04 | 1,967.48 | 1,681.93 | 1,183.33 | |
| CURRENT INVESTMENTS | ||||||
| Current Investments Quoted Market Value | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | |
| Current Investments Unquoted Book Value | -- | -- | -- | -- | -- |
07.11.2025
Aurobindo Pharm Consolidated September 2025 Net Sales at Rs 8,285.70 crore, up 6.28% Y-o-Y
03.11.2025
09.10.2025
11.09.2025
Aurobindo Pharma shares rise 4.5% as report says GTCR strikes $4.8-bn deal to buy Zentiva
07.11.2025
Aurobindo Pharm Consolidated September 2025 Net Sales at Rs 8,285.70 crore, up 6.28% Y-o-Y
12.08.2025
Aurobindo Pharm Consolidated June 2025 Net Sales at Rs 7,868.14 crore, up 3.98% Y-o-Y
05.08.2025
Aurobindo Pharm Standalone June 2025 Net Sales at Rs 2,848.17 crore, up 15.78% Y-o-Y
27.05.2025
Aurobindo Pharm Standalone March 2025 Net Sales at Rs 2,731.99 crore, down 5.6% Y-o-Y
14.07.2023
Cipla Q1 PAT seen up 6.1% YoY to Rs. 552.3 cr: Prabhudas Lilladher
14.07.2023
Aurobindo Pharma Q1 PAT seen up 6.1% YoY to Rs. 552.3 cr: Prabhudas Lilladher
13.07.2022
Aurobindo Q1 PAT may dip 26.1% YoY to Rs 568.8 cr: ICICI Direct
08.07.2022
Aurobindo Pharma Q1 PAT may dip 20.7% YoY to Rs 610.7 cr: Prabhudas Lilladher
11.02.2019
Analysts remain positive on Aurobindo Pharma, expect stock to return 8-30% after Q3 earnings
25.08.2018
Pharma Q1 review: Brokerages say performance a mixed bag, but are upbeat on domestic biz
10.08.2017
When Rakesh Jhunjhunwala grilled Aurobindo Pharma top brass after muted Q1 results
24.08.2016
Aurobindo to see growth in H2; capacity constraints continue: PL